Lifecore Biomedical Stock Beneish M Score

LFCR Stock   7.50  0.06  0.81%   
This module uses fundamental data of Lifecore Biomedical to approximate the value of its Beneish M Score. Lifecore Biomedical M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Lifecore Biomedical Piotroski F Score and Lifecore Biomedical Altman Z Score analysis.
To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.
  
At this time, Lifecore Biomedical's Net Debt is relatively stable compared to the past year. As of 11/28/2024, Long Term Debt is likely to grow to about 123.4 M, while Short and Long Term Debt Total is likely to drop slightly above 66 M. As of 11/28/2024, Average Receivables is likely to drop to about 20.2 M
At this time, it appears that Lifecore Biomedical is an unlikely manipulator. The earnings manipulation may begin if Lifecore Biomedical's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Lifecore Biomedical executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Lifecore Biomedical's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-2.8
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables

1.14

Focus
Asset Quality

0.58

Focus
Expense Coverage

1.4

Focus
Gross Margin Strengs

0.52

Focus
Accruals Factor

1.4

Focus
Depreciation Resistance

1.48

Focus
Net Sales Growth

0.95

Focus
Financial Leverage Condition

1.25

Focus

Lifecore Biomedical Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Lifecore Biomedical's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables33.9 M31.2 M
Significantly Up
Pretty Stable
Total Revenue121.8 M128.3 M
Notably Down
Pretty Stable
Total Assets248.7 M273.7 M
Moderately Down
Slightly volatile
Total Current Assets86.2 M81 M
Notably Up
Slightly volatile
Non Current Assets Total161.8 M172.9 M
Notably Down
Pretty Stable
Property Plant Equipment132.6 M121.1 M
Significantly Up
Slightly volatile
Selling General Administrative57.3 M43 M
Significantly Up
Slightly volatile
Total Current Liabilities55 M38.9 M
Significantly Up
Slightly volatile
Non Current Liabilities Total190 M180.9 M
Sufficiently Up
Slightly volatile
Short Term Debt4.7 M4.9 M
Notably Down
Slightly volatile
Long Term Debt123.4 M120.5 M
Fairly Up
Slightly volatile
Short Term Investments1.7 M1.8 M
Notably Down
Very volatile
Long Term Investments43.5 M40.6 M
Notably Up
Slightly volatile
Gross Profit Margin0.170.3263
Way Down
Slightly volatile

Lifecore Biomedical Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Lifecore Biomedical's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Lifecore Biomedical in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Lifecore Biomedical's degree of accounting gimmicks and manipulations.

About Lifecore Biomedical Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

6.39 Million

At this time, Lifecore Biomedical's Depreciation And Amortization is relatively stable compared to the past year.

Lifecore Biomedical Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Lifecore Biomedical. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201920202021202220232024 (projected)
Net Receivables76.2M41.4M48.2M38.3M31.2M33.9M
Total Revenue557.6M590.4M544.2M185.8M128.3M121.8M
Total Assets541.3M502.9M295.2M295.4M273.7M248.7M
Total Current Assets157.1M148.3M123.7M124.0M81.0M86.2M
Net Debt220.8M220.1M151.5M151.4M121.9M128.0M
Short Term Debt93.4M30.6M45.6M142.5M4.9M4.7M
Long Term Debt101.4M164.9M97.6M101.3M120.5M123.4M
Operating Income(8.3M)(6.9M)(3.6M)3.5M9.3M5.7M

Lifecore Biomedical ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lifecore Biomedical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lifecore Biomedical's managers, analysts, and investors.
Environmental
Governance
Social

About Lifecore Biomedical Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lifecore Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lifecore Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lifecore Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Lifecore Biomedical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lifecore Biomedical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lifecore Biomedical will appreciate offsetting losses from the drop in the long position's value.

Moving together with Lifecore Stock

  0.84BMY Bristol Myers Squibb Aggressive PushPairCorr

Moving against Lifecore Stock

  0.92PEPG PepGenPairCorr
  0.84MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.82JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.77NKTX Nkarta Inc Buyout TrendPairCorr
  0.75MREO Mereo BioPharma GroupPairCorr
The ability to find closely correlated positions to Lifecore Biomedical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lifecore Biomedical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lifecore Biomedical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lifecore Biomedical to buy it.
The correlation of Lifecore Biomedical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lifecore Biomedical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lifecore Biomedical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lifecore Biomedical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Lifecore Stock Analysis

When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.